$ANIP
ANI PHARMACEUTICALS INC Stock $anip

$anip Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000102302424000026 Filed on February 29, 2024

Income Statement

Concept	2023 Q4	2023	2022
Revenue	$131.7M	$486.8M	$316.4M
YoY Change	39.71%	53.87%	46.38%
Cost Of Revenue	$53.42M	$181.5M	$138.8M
YoY Change	47.06%	30.79%	37.94%
Gross Profit	$78.23M	$305.3M	$177.6M
YoY Change	35.11%	71.9%	53.73%
Gross Profit Margin	59.42%	62.71%	56.13%
Selling, General & Admin	$44.46M	$161.7M	$124.0M
YoY Change	33.97%	30.35%	47.16%
% of Gross Profit	56.83%	52.96%	69.84%
Research & Development	$9.867M	$34.29M	$22.30M
YoY Change	88.95%	53.75%	95.61%
% of Gross Profit	12.61%	11.23%	12.56%
Depreciation & Amortization	$15.19M	$7.500M	$7.400M
YoY Change	-2.43%	1.35%	-84.34%
% of Gross Profit	19.42%	2.46%	4.17%
Operating Expenses	$71.51M	$196.0M	$146.3M
YoY Change	31.16%	33.92%	52.93%
Operating Profit	$6.726M	$46.97M	-$35.28M
YoY Change	98.52%	-233.13%	-11.33%
Interest Expense	-$5.746M	-$26.94M	-$28.05M
YoY Change	-23.45%	-3.96%	135.3%
% of Operating Profit	-85.43%	-57.35%
Other Income/Expense, Net	-$33.00K	-$159.0K	$670.0K
YoY Change	-21.43%	-123.73%	-115.43%
Pretax Income	$947.0K	$19.87M	-$62.67M
YoY Change	-116.53%	-131.71%	11.79%
Income Tax	-$208.0K	$1.093M	-$14.77M
% Of Pretax Income	-21.96%	5.5%
Net Earnings	$699.0K	$18.78M	-$47.90M
YoY Change	-115.03%	-139.21%	12.42%
Net Earnings / Revenue	0.53%	3.86%	-15.14%
Basic Earnings Per Share		$0.86	-$3.05
Diluted Earnings Per Share	$0.04	$0.85	-$3.05
COMMON SHARES
Basic Shares Outstanding		18.00M shares	16.26M
Diluted Shares Outstanding		18.19M shares	16.26M

Balance Sheet

Concept	2023 Q4	2023	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$221.1M	$221.1M	$48.23M
YoY Change	358.49%	358.49%	-51.92%
Cash & Equivalents	$221.1M	$221.1M	$48.23M
Short-Term Investments
Other Short-Term Assets	$25.42M	$25.42M	$21.41M
YoY Change	18.71%	18.71%	182.16%
Inventory	$111.2M	$111.2M	$105.4M
Prepaid Expenses	$17.40M
Receivables	$162.1M	$162.1M	$165.4M
Other Receivables	$0.00	$0.00	$3.827M
Total Short-Term Assets	$519.8M	$519.8M	$344.3M
YoY Change	50.99%	50.99%	6.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$44.59M	$44.59M	$43.25M
YoY Change	3.11%	3.11%	-17.89%
Goodwill	$28.20M
YoY Change	0.0%
Intangibles	$209.0M
YoY Change	-16.94%
Long-Term Investments
YoY Change
Other Assets	$12.07M	$102.8M	$92.72M
YoY Change	6.26%	10.85%	23.4%
Total Long-Term Assets	$384.6M	$384.6M	$415.8M
YoY Change	-7.51%	-7.51%	-7.56%
TOTAL ASSETS
Total Short-Term Assets	$519.8M	$519.8M	$344.3M
Total Long-Term Assets	$384.6M	$384.6M	$415.8M
Total Assets	$904.4M	$904.4M	$760.1M
YoY Change	18.99%	18.99%	-1.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$36.68M	$36.68M	$29.31M
YoY Change	25.18%	25.18%	27.6%
Accrued Expenses	$5.606M	$57.84M	$35.89M
YoY Change	3.93%	61.17%	29.07%
Deferred Revenue	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$850.0K	$850.0K	$850.0K
YoY Change	0.0%	0.0%	0.0%
Total Short-Term Liabilities	$145.5M	$145.5M	$99.44M
YoY Change	46.3%	46.3%	13.6%
LONG-TERM LIABILITIES
Long-Term Debt	$284.8M	$284.8M	$285.7M
YoY Change	-0.3%	-0.3%	-0.3%
Other Long-Term Liabilities	$4.809M	$16.53M	$36.44M
YoY Change	248.23%	-54.64%	-6.09%
Total Long-Term Liabilities	$289.6M	$301.3M	$322.1M
YoY Change	0.9%	-6.45%	-0.99%
TOTAL LIABILITIES
Total Short-Term Liabilities	$145.5M	$145.5M	$99.44M
Total Long-Term Liabilities	$289.6M	$301.3M	$322.1M
Total Liabilities	$446.8M	$446.8M	$421.5M
YoY Change	6.0%	6.0%	2.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$80.13M
YoY Change	-17.63%
Common Stock	$2.000K
YoY Change	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$432.7M	$457.6M	$338.5M
YoY Change
Total Liabilities & Shareholders Equity	$904.4M	$904.4M	$760.1M
YoY Change	18.99%	18.99%	-1.49%

Cashflow Statement

Concept	2023 Q4	2023	2022
OPERATING ACTIVITIES
Net Income	$699.0K	$18.78M	-$47.90M
YoY Change	-115.03%	-139.21%	12.42%
Depreciation, Depletion And Amortization	$15.19M	$7.500M	$7.400M
YoY Change	-2.43%	1.35%	-84.34%
Cash From Operating Activities	$44.74M	$119.0M	-$31.20M
YoY Change	-1116.82%	-481.24%	-1039.28%
INVESTING ACTIVITIES
Capital Expenditures	$2.279M	$8.868M	$8.876M
YoY Change	-27.37%	-0.09%	247.13%
Acquisitions		$0.00	$33.00K
YoY Change		-100.0%	-99.96%
Other Investing Activities	-$2.500M	-$9.643M	-$6.862M
YoY Change	62400.0%	40.53%	-93.33%
Cash From Investing Activities	-$4.779M	-$18.51M	-$15.74M
YoY Change	52.1%	17.62%	-85.08%
FINANCING ACTIVITIES
Cash Dividend Paid		$1.625M	$1.625M
YoY Change		0.0%	755.26%
Common Stock Issuance & Retirement, Net		-$75.57M	$1.959M
YoY Change		-3957.48%	-102.64%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-11.92M	$67.44M	-5.126M
YoY Change	2246.06%	-1415.63%	-102.63%
NET CHANGE
Cash From Operating Activities	44.74M	$119.0M	-31.20M
Cash From Investing Activities	-4.779M	-$18.51M	-15.74M
Cash From Financing Activities	-11.92M	$67.44M	-5.126M
Net Change In Cash	28.04M	$167.9M	-52.07M
YoY Change	-448.36%	-422.44%	-156.33%
FREE CASH FLOW
Cash From Operating Activities	$44.74M	$119.0M	-$31.20M
Capital Expenditures	$2.279M	$8.868M	$8.876M
Free Cash Flow	$42.46M	$110.1M	-$40.08M
YoY Change	-663.29%	-374.68%	-5339.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1625000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	17154000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-49521000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.86
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.05
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.40
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.05
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16260000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12596000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12596000	shares
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	190000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2069000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	890000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5126000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	167887000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-52067000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53234000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105301000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12867000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	18779000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47896000	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1625000	usd
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	190000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42793000	usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.40
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001023024
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
CY2023	us-gaap	Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-31812
CY2023	dei	Entity Registrant Name EntityRegistrantName	ANI PHARMACEUTICALS, INC
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2301143
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 Main Street West
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Baudette
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	56623
CY2023	dei	City Area Code CityAreaCode	218
CY2023	dei	Local Phone Number LocalPhoneNumber	634-3500
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	ANIP
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	824200000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	221121000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48228000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5006000	usd
CY2023Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	97262000	usd
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	161052000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	162079000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	165438000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	111196000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	105355000	usd
CY2023Q4	anip	Prepaid Income Taxes Net PrepaidIncomeTaxesNet	0	usd
CY2022Q4	anip	Prepaid Income Taxes Net PrepaidIncomeTaxesNet	3827000	usd
CY2023Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	8020000	usd
CY2022Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	8020000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	17400000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8387000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	519816000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	344261000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44593000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43246000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	90711000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	81363000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	209009000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	251635000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	28221000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	28221000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12072000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11361000	usd
CY2023Q4	us-gaap	Assets Assets	904422000	usd
CY2022Q4	us-gaap	Assets Assets	760087000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	850000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	850000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	36683000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	29305000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	16276000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	9307000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23786000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10312000	usd
CY2023Q4	anip	Accrued Government Rebates AccruedGovernmentRebates	12168000	usd
CY2022Q4	anip	Accrued Government Rebates AccruedGovernmentRebates	10872000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	8164000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	usd
CY2023Q4	anip	Returned Goods Reserve ReturnedGoodsReserve	29678000	usd
CY2022Q4	anip	Returned Goods Reserve ReturnedGoodsReserve	33399000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	12266000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5606000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5394000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	145477000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	99439000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	284819000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	285669000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	11718000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	35058000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4809000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1381000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	446823000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	421547000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	24850000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	24850000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	anip	Class C Special Stock Value ClassCSpecialStockValue	0	usd
CY2022Q4	anip	Class C Special Stock Value ClassCSpecialStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	263943	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	149031	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	10081000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	5094000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	514103000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	403901000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80132000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97286000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8857000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	12168000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	432749000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	313690000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	904422000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	760087000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	216136000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	161697000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	59791000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	56972000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1426000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3758000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	500000	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-8750000	usd
CY2023	anip	Cortrophin Pre Launch Charges CortrophinPreLaunchCharges	0	usd
CY2022	anip	Cortrophin Pre Launch Charges CortrophinPreLaunchCharges	0	usd
CY2021	anip	Cortrophin Pre Launch Charges CortrophinPreLaunchCharges	780000	usd
CY2021	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	112000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2374000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	46971000	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-11922000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1093000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18001000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18194000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16260000	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	18779000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47896000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-42603000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	44000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-112000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	12000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-3355000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	15335000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	8370000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3311000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	15223000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	8382000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	15468000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32673000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34221000	usd
CY2020Q4	anip	Stockholders Equity Attributable To Parent And Temporary Equity StockholdersEquityAttributableToParentAndTemporaryEquity	195700000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10489000	usd
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	889000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2069000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	1000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	69734000	usd
CY2021	us-gaap	Dividends Preferred Stock DividendsPreferredStock	190000	usd
CY2021	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	24850000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	8382000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-42603000	usd
CY2021Q4	anip	Stockholders Equity Attributable To Parent And Temporary Equity StockholdersEquityAttributableToParentAndTemporaryEquity	358740000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14599000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1959000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1458000	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1625000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	15223000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-47896000	usd
CY2022Q4	anip	Stockholders Equity Attributable To Parent And Temporary Equity StockholdersEquityAttributableToParentAndTemporaryEquity	338540000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20652000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	1000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	80556000	usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1625000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3311000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	18779000	usd
CY2023Q4	anip	Stockholders Equity Attributable To Parent And Temporary Equity StockholdersEquityAttributableToParentAndTemporaryEquity	457599000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	18779000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-47896000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-42603000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	20652000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	14599000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10489000	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-11740000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-15253000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-16754000	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	59791000	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	59653000	usd
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	47252000	usd
CY2023	anip	Acquired In Process Reserach And Development Expense AcquiredInProcessReserachAndDevelopmentExpense	0	usd
CY2022	anip	Acquired In Process Reserach And Development Expense AcquiredInProcessReserachAndDevelopmentExpense	1151000	usd
CY2021	anip	Acquired In Process Reserach And Development Expense AcquiredInProcessReserachAndDevelopmentExpense	0	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1269000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3922000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3961000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2512000	usd
CY2023	anip	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Cash Flow BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow	1426000	usd
CY2022	anip	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Cash Flow BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow	4058000	usd
CY2021	anip	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Cash Flow BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow	500000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1458000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	574000	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	2374000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	750000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1822000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3359000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	36912000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5548000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5841000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	23626000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3224000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	9015000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	798000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-127000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7552000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5038000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10166000	usd
CY2023	anip	Increase Decrease In Royalty Payable IncreaseDecreaseInRoyaltyPayable	6969000	usd
CY2022	anip	Increase Decrease In Royalty Payable IncreaseDecreaseInRoyaltyPayable	3082000	usd
CY2021	anip	Increase Decrease In Royalty Payable IncreaseDecreaseInRoyaltyPayable	-267000	usd
CY2023	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	11991000	usd
CY2022	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-160000	usd
CY2021	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-7573000	usd
CY2023	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	1296000	usd
CY2022	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	5380000	usd
CY2021	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	-3078000	usd
CY2023	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	-3722000	usd
CY2022	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	-2399000	usd
CY2021	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	6503000	usd
CY2023	anip	Increase Decrease Of Accrued Expenses Compensation And Others IncreaseDecreaseOfAccruedExpensesCompensationAndOthers	12271000	usd
CY2022	anip	Increase Decrease Of Accrued Expenses Compensation And Others IncreaseDecreaseOfAccruedExpensesCompensationAndOthers	-905000	usd
CY2021	anip	Increase Decrease Of Accrued Expenses Compensation And Others IncreaseDecreaseOfAccruedExpensesCompensationAndOthers	-3638000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	118959000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31203000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3322000	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	33000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	84494000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	9643000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7579000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	21081000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8868000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8876000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2557000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	750000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2649000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18511000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15738000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-105483000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	80555000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	69584000	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	12500000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
CY2023	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	usd
CY2022	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	usd
CY2021	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	10862000	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	3000000	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	3000000	usd
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
CY2023	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	usd
CY2021	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	24000000	usd
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	200148000	usd
CY2023	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	286032000	usd
CY2023	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	25000000	usd
CY2023	us-gaap	Payments Of Dividends PaymentsOfDividends	1625000	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	1625000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8996000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1458000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4987000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1959000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	67439000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	194595000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	92434000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	221121000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53234000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105301000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48228000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100300000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7864000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5006000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5001000	usd
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5003000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53234000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105301000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	221121000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48228000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100300000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5006000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5001000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	221121000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53234000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105301000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	31431000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	21477000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	9705000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	1228000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	288000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	10371000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4715000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	0	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	0	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	30500000	usd
CY2023	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	0	usd
CY2022	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	0	usd
CY2021	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	91199000	usd
CY2023	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	1000000	usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	328000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	452000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	152000	usd
CY2023Q4	anip	Number Of Pharmaceutical Manufacturing Facilities NumberOfPharmaceuticalManufacturingFacilities	3	facility
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. In the consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and potential adjustments, income tax expense or benefit, deferred taxes and valuation allowance, stock-based compensation, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates.
CY2023Q4	anip	Fdic Guaranteed Amount FDICGuaranteedAmount	250000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	100000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2400000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Derivatives Methods Of Accounting Hedging Derivatives DerivativesMethodsOfAccountingHedgingDerivatives	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedge Accounting</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses interest rate swaps to hedge exposure to interest rate risk, as well as benefit from favorable conditions. The Company recognizes all derivative instruments as either assets or liabilities at fair value. For all of the Company’s derivative positions that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivatives is reported as a component of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on derivatives representing any ineffective component of the hedge are recognized in current earnings. All of the Company’s cash flow hedges have been deemed effective as of December 31, 2023 for both accounting and tax purposes. The Company has elected hedge accounting for both U.S. GAAP and tax purposes. The Company maintains formal documentation through a periodic memo and accounting analysis that cover what is being hedged, how it is being hedged, hedge effectiveness, the nature of the risk being hedged, among other required analyses. Company policy further includes a quarterly probability analysis covering hedge effectiveness.</span></div>
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	486816000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	316385000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	216136000	usd
CY2023	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	4100000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	272888000	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-31740000	usd
CY2023Q4	anip	Number Of Pharmaceutical Manufacturing Facilities NumberOfPharmaceuticalManufacturingFacilities	3	facility
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	30692000	usd
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	26150000	usd
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	11129000	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2364000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2363000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	914000	usd
CY2023	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	587000	usd
CY2022	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	95000	usd
CY2021	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	98000	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	32469000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	28418000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	11945000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	62237000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	67726000	usd
CY2023Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	9617000	usd
CY2022Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	7720000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3144000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1889000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	36198000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	28020000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	111196000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	105355000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	77528000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	75958000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32935000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32712000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44593000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43246000	usd
CY2023	us-gaap	Depreciation Depreciation	7500000	usd
CY2022	us-gaap	Depreciation Depreciation	7400000	usd
CY2021	us-gaap	Depreciation Depreciation	5500000	usd
CY2023	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	600000	usd
CY2022	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	100000	usd
CY2021	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	100000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q4	us-gaap	Goodwill Goodwill	28200000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	28200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	497332000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	308123000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	189209000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	480915000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	255855000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	225060000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P4Y6M
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	517132000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	308123000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	209009000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	507490000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	255855000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	251635000	usd
CY2023	us-gaap	Finite Lived Intangible Assets Period Increase Decrease FiniteLivedIntangibleAssetsPeriodIncreaseDecrease	16400000	usd
CY2023	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	9600000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	52300000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	49500000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	41800000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	50364000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	47128000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	33643000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	24677000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	17895000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	15502000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	189209000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	100000	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2400000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	191800000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-49521000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42793000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	17154000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-49521000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-42793000	usd
CY2023	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	1679000	usd
CY2022	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	usd
CY2021	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	usd
CY2023	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	1663000	usd
CY2022	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	0	usd
CY2021	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	0	usd
CY2023	us-gaap	Undistributed Earnings UndistributedEarnings	15475000	usd
CY2022	us-gaap	Undistributed Earnings UndistributedEarnings	-49521000	usd
CY2021	us-gaap	Undistributed Earnings UndistributedEarnings	-42793000	usd
CY2023	us-gaap	Undistributed Earnings Diluted UndistributedEarningsDiluted	15491000	usd
CY2022	us-gaap	Undistributed Earnings Diluted UndistributedEarningsDiluted	-49521000	usd
CY2021	us-gaap	Undistributed Earnings Diluted UndistributedEarningsDiluted	-42793000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18001000	shares
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	35058000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	31000000	usd
CY2023	anip	Fair Value Measurement With Unobservable Inputs Reconciliation Measurement Period Adjustment FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment	0	usd
CY2022	anip	Fair Value Measurement With Unobservable Inputs Reconciliation Measurement Period Adjustment FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment	300000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	12500000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	0	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1426000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	3758000	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	23984000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	35058000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	191841000	usd
CY2023Q4	us-gaap	Interest Rate Derivative Assets At Fair Value InterestRateDerivativeAssetsAtFairValue	6236000	usd
CY2022Q4	us-gaap	Interest Rate Derivative Assets At Fair Value InterestRateDerivativeAssetsAtFairValue	8759000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1700000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1700000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	anip	Common Stock Convertible Conversion Ratio CommonStockConvertibleConversionRatio	1
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	17154000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16260000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12596000	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18001000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16260000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12596000	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	193000	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18194000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16260000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12596000	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.86
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.05
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.40
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.05
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.40
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2400000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2600000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1700000	shares
CY2023	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	3300000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1700000	usd
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1000000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-13455000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15232000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-16949000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-187000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1093000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-14769000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	9117000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	152000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1296000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3534000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	249000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1320000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	26000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	66000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	691000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	12677000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	467000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3307000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7601000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-13382000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-12163000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3946000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1722000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-5122000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-29000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-128000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	336000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-11576000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.032
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.033
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.010
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.003
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.108
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.014
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.017
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.021
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.008
CY2023	anip	Effective Income Tax Rate Reconciliation State And Foreign Income Taxes EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes	-0.118
CY2022	anip	Effective Income Tax Rate Reconciliation State And Foreign Income Taxes EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes	-0.001
CY2021	anip	Effective Income Tax Rate Reconciliation State And Foreign Income Taxes EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes	0.055
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.190
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.014
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.009
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.024
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.029
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.055
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.236
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.240
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	12470000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	9233000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6013000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6041000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	17358000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	15344000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	4569000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	5292000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	40193000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	33431000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5994000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	11294000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4708000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7450000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11840000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	102247000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	91883000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5658000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5776000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	5440000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	4298000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11098000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10074000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	438000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	446000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	90711000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	81363000	usd
CY2023Q4	anip	Number Of Operating Leases NumberOfOperatingLeases	14	operatinglease
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0812
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0399
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2031000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	701000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	240000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	221000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	236000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	48000	usd
CY2023	us-gaap	Lease Cost LeaseCost	2252000	usd
CY2022	us-gaap	Lease Cost LeaseCost	937000	usd
CY2021	us-gaap	Lease Cost LeaseCost	288000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1967000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1610000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1290000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1289000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	506000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6662000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	990000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5672000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1561000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4111000	usd
CY2023Q4	anip	Number Of Products Marketed NumberOfProductsMarketed	3	product
CY2020Q4	us-gaap	Loss Contingency Number Of Plaintiffs LossContingencyNumberOfPlaintiffs	6	plaintiff
CY2012	anip	Loss Contingency Number Of Manufacturers LossContingencyNumberOfManufacturers	7	manufacturer
	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	5	claim
	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	5	claim
CY2021Q3	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	158	claim
CY2021Q3	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	158	claim
CY2022Q3	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	6	claim
CY2022Q3	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	7	claim
CY2023Q4	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	200	claim
CY2022Q3	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	2	claim
CY2021	anip	Cortrophin Pre Launch Charges CortrophinPreLaunchCharges	800000	usd
CY2023Q4	anip	Number Of Executive Founders NumberOfExecutiveFounders	2	founder
CY2021Q4	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	486816000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	316385000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	216136000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	46971000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-35283000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-39793000	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-26940000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-28052000	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-11922000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-159000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	670000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4343000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	19872000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-62665000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-56058000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	486816000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	316385000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	216136000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44593000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43246000	usd
CY2023	dei	Auditor Name AuditorName	EisnerAmper LLP
CY2023	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2023	dei	Auditor Firm AuditorFirmId	274

Files In Submission

Name	View Source	Status
anip-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001023024-24-000026-index-headers.html	Edgar Link	pending
0001023024-24-000026-index.html	Edgar Link	pending
0001023024-24-000026.txt	Edgar Link	pending
0001023024-24-000026-xbrl.zip	Edgar Link	pending
anip-20231231.htm	Edgar Link	pending
anip-20231231.xsd	Edgar Link	pending
anip-20231231xexx1032.htm	Edgar Link	pending
anip-20231231xexx1033.htm	Edgar Link	pending
anip-20231231xexx1034.htm	Edgar Link	pending
anip-20231231xexx21.htm	Edgar Link	pending
anip-20231231xexx311.htm	Edgar Link	pending
anip-20231231xexx312.htm	Edgar Link	pending
anip-20231231xexx321.htm	Edgar Link	pending
anip-20231231xexx971.htm	Edgar Link	pending
anip-20231231_g1.jpg	Edgar Link	pending
anip-2023x1231xexx1024.htm	Edgar Link	pending
anip-2023x1231xexx1031.htm	Edgar Link	pending
anip-2023x1231xexx231.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
anip-20231231_def.xml	Edgar Link	unprocessable
anip-20231231_lab.xml	Edgar Link	unprocessable
anip-20231231_pre.xml	Edgar Link	unprocessable
anip-20231231_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIP
ANI PHARMACEUTICALS INC Stock $anip

2023 Q4 Form 10-K Financial Statement

#000102302424000026 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP ANI PHARMACEUTICALS INC Stock $anip

2023 Q4 Form 10-K Financial Statement

#000102302424000026 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP
ANI PHARMACEUTICALS INC Stock $anip